Publication details
Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno
| Title in English | Treatment with bevacizumab in combination with carboplatin and oral vinorelbine in patients with non-small cell lung cancer (NSCLC) at the Department of Pulmonary Diseases and TB, Masaryk University Faculty of Medicine and University Hospital, Brno |
|---|---|
| Authors | |
| Year of publication | 2019 |
| Type | Article in Periodical |
| Magazine / Source | Studia pneumologica et phthiseologica |
| MU Faculty or unit | |
| Citation | |
| Web | Scopus |
| Keywords | Advanced non-small cell lung cancer; Bevacizumab; Carboplatin; Oral vinorelbine; Treatment |
| Description | For patients with advanced NSCLC of non-squamous morphological diagnosis in whom neither epidermal growth factor receptor-activating mutation nor anaplastic lymphoma kinase gene rearrangement have been found, one possible treatment option is platinum-based chemotherapy in combination with bevacizumab. If after 4 to 6 cycles of this treatment, regression or disease stabilization is achieved, bevacizumab is further given as monotherapy (maintenance follow-up treatment). If bevacizumab treatment is indicated, the most common combination used in our center is bevacizumab with carboplatin and oral vinorelbine. The primary aim of the study was to evaluate the efficacy and safety of this approach. Treatment of 70 patients with advanced non-squamous NSCLC with the above combination was effective. So far, the median time to progression has been 5.1 months and the median survival 20.5 months. The therapy is very well tolerated. |